α-NETA is a potent, irreversible and noncompetitive inhibitor of choline acetyltransferase (ChA) with an IC50 of 9 μM. It is also a potent antagonist of ALDH1A1, CMKLR1, and G9a histone methyltransferase with an IC50 of 0.04 µM, 0.38 µM, and 0.50 µM, respectively. It exhibits anti-cancer activity and may be beneficial in preventing or treating multiple sclerosis (MS).

α-NETA is a potent, irreversible and noncompetitive inhibitor of choline acetyltransferase (ChA) with an IC50 of 9 μM. It is also a potent antagonist of ALDH1A1, CMKLR1, and G9a histone methyltransferase with an IC50 of 0.04 µM, 0.38 µM, and 0.50 µM, respectively. It exhibits anti-cancer activity and may be beneficial in preventing or treating multiple sclerosis (MS).

SMS121 is a potent inhibitor of CD36 with a Kd value of 5.57 µM. It impairs fatty acid uptake, as well as the viability and proliferation of acute myeloid leukemia (AML) cells, indicating its potential as a future therapeutic agent against AML.

α-NETA is a potent, irreversible and noncompetitive inhibitor of choline acetyltransferase (ChA) with an IC50 of 9 μM. It is also a potent antagonist of ALDH1A1, CMKLR1, and G9a histone methyltransferase with an IC50 of 0.04 µM, 0.38 µM, and 0.50 µM, respectively. It exhibits anti-cancer activity and may be beneficial in preventing or treating multiple sclerosis (MS).

SMS121 is a potent inhibitor of CD36 with a Kd value of 5.57 µM. It impairs fatty acid uptake, as well as the viability and proliferation of acute myeloid leukemia (AML) cells, indicating its potential as a future therapeutic agent against AML.

SMS121 is a potent inhibitor of CD36 with a Kd value of 5.57 µM. It impairs fatty acid uptake, as well as the viability and proliferation of acute myeloid leukemia (AML) cells, indicating its potential as a future therapeutic agent against AML.

SMS121 is a potent inhibitor of CD36 with a Kd value of 5.57 µM. It impairs fatty acid uptake, as well as the viability and proliferation of acute myeloid leukemia (AML) cells, indicating its potential as a future therapeutic agent against AML.

T26( PARP1-IN-35) is a potent, selective, orally active, inhibitor of PARP1 capable of crossing the blood-brain barrier, with IC50 values of 0.2 nM. It exhibits significant antitumor efficacy and holds potential as a research treatment for breast cancer metastases.

T26( PARP1-IN-35) is a potent, selective, orally active, inhibitor of PARP1 capable of crossing the blood-brain barrier, with IC50 values of 0.2 nM. It exhibits significant antitumor efficacy and holds potential as a research treatment for breast cancer metastases.

T26( PARP1-IN-35) is a potent, selective, orally active, inhibitor of PARP1 capable of crossing the blood-brain barrier, with IC50 values of 0.2 nM. It exhibits significant antitumor efficacy and holds potential as a research treatment for breast cancer metastases.